B
BioQ Pharma
About BioQ Pharma
BioQ Pharma is a commercial stage company that operates in the pharmaceutical industry, specifically in the infusion medicine sector. Their proprietary platform, invenious™, is designed to transform infusible medicines into ready-to-use systems. This means that the medicines are pre-filled and ready to be administered, making the process more efficient, safer, and simpler for both healthcare providers and patients.
The company's business model revolves around the invenious™ platform, which offers a unique 'connect-and-go' delivery solution for infusible medicines. This system is particularly beneficial for medicines that are difficult to prepare or administer, providing a more streamlined and user-friendly approach. The platform also allows for the delivery of infusible drugs with specifically designed systems tailored for each drug, enhancing the overall efficiency and safety of the administration process.
BioQ Pharma generates revenue by selling their invenious™ delivery systems to healthcare providers and payers. The company also presents the opportunity to build on existing product claims with new benefits to administration, which could potentially lead to increased market share and profitability.
In terms of clientele, BioQ Pharma primarily serves healthcare providers who administer infusible medicines, as well as payers who are looking for more efficient and safer delivery systems. The company operates in the global pharmaceutical market, with a focus on infusion medicine.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2003
- Headquarters
- San Francisco, United States
- Employees
- 2
- Open positions
- None listed
- Dealroom signal
- 54.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBTDebt | Jan 2020 | $19M | — | Undisclosed | ↗ |
| LATE VCOther financing | Aug 2017 | $55M | $220M | Madryn Asset Management | ↗ |
Growth signals
Latest recorded traffic for BioQ Pharma is 1.3K monthly website visits, up 113.1% over the last three months. BioQ Pharma's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Lesmoir-Gordon, Boyle & Co.
Series B and later1 investor entered at this stage
Madryn Asset Management
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about BioQ Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioQ Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.